Stay updated on Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.0%
    Check dated 2024-06-13T22:34:42.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a recent update in the study details of a Phase 3 clinical trial comparing the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
    Difference
    0.0%
    Check dated 2024-06-06T14:38:36.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value 'Participation Criteria 6' has been updated to 'Participation Criteria Researchers look for people who fit a certain description, called eligibility criteria.' This change includes a detailed description of eligibility criteria, such as a person's general health condition or prior treatments, and provides a link for general information about clinical research.
    Difference
    27%
    Check dated 2024-05-22T20:33:40.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.4%
    Check dated 2024-04-30T21:52:06.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Premenopausal HR+/HER2- Breast Cancer Clinical Trial page.